Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2025 06:00 ET | Source: Belite Bio, Inc

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in adolescent Stargardt 1 (STGD1) subjects, proceed without...
March 11, 2025 03:00 ET | Source: Belite Bio, Inc

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
March 04, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in the Leerink Partners Global Healthcare Conference

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
February 27, 2025 02:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects

An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned...
February 05, 2025 22:35 ET | Source: Belite Bio, Inc

Belite Bio Announces Registered Direct Offering of $15 Million

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel...
November 12, 2024 01:00 ET | Source: Belite Bio, Inc

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is...
November 05, 2024 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
November 03, 2024 16:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel...
October 14, 2024 08:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel...
October 08, 2024 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...